Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma.

In 190 people with stage I to IIIB melanoma (1,578 samples), postoperative ctDNA measured with a tumor-informed 16-plex PCR sequencing assay was associated with shorter recurrence-free survival (HR 40.63).

Clinical Cancer ResearchPubMed 41632449DOI 10.1158/1078-0432.CCR-25-3643